(Q46514972)

English

Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme

scientific article published in June 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

0 references

object named as

John McMurray

12

0 references

14

object named as

Karl Swedberg

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

13

object named as

Salim Yusuf

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

15

object named as

Marc A Pfeffer

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Robert S McKelvie

5

object named as

Robert S McKelvie

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

2

object named as

Eldrin Lewis

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Eric L Michelson

8

object named as

Eric L Michelson

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Jeffrey L Probstfield

6

object named as

Jeffrey L Probstfield

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

4

object named as

Mark E Dunlap

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Jonas Carlsson Almlöf

10

object named as

Jonas Carlsson

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

3

object named as

Chris Granger

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

author name string

Eileen O'Meara

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

James B Young

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Jan Ostergren

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Bertil Olofsson

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

European Journal of Heart Failure

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

650-656

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) pro

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Beta-blockers for chronic heart failure: surviving longer but feeling better?

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.01.021

21 January 2018

Identifiers

10.1016/J.EJHEART.2005.01.021

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921807

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46514972&oldid=2115650319"